Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

DFTX

Definium Therapeutics Inc

45.98

Jul 14 • 03:59PM ET +2.33 (5.34%)

45.90

Aftermarket • 07:44PM ET -0.08 (-0.17%)

Healthcare Biotechnology USA Mid NASD

Peers: KYMR NUVL INCY RYTM APGE KRYS VKTX BMRN AXSM NBIX

| Held by: IWM IWO IBB VXF SCHA IHE FESM CGMM XPH VTWO

Index	RUT
Market Cap	6.10B
Enterprise Value	5.77B
Income	-237.54M
Sales	0.00M
Book/sh	2.68
Cash/sh	2.81
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	106
IPO	Nov 15, 2016

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	17.16
P/C	16.34
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	4.69
Current Ratio	4.69
Debt/Eq	0.15
LT Debt/Eq	0.15
Option/Short	Yes / Yes

EPS (ttm)	-2.50
EPS next Y	-1.60
EPS next Q	-0.56
EPS this Y	-8.06%
EPS next Y	28.26%
EPS next 5Y	30.70%
EPS past 3/5Y	-3.78% -1.48%
Sales past 3/5Y	- -
EPS Y/Y TTM	-164.79%
Sales Y/Y TTM	-
EPS Q/Q	-158.18%
Sales Q/Q	-
Earnings	May 07 AMC
EPS/Sales Surpr.	-44.28% -

Insider Own	4.97%
Insider Trans	-1.51%
Inst Own	57.33%
Inst Trans	8.60%
ROA	-70.22%
ROE	-94.70%
ROIC	-74.32%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	14.66%
SMA50	55.26%
SMA200	141.34%
Trades

Shs Outstand	132.74M
Shs Float	126.14M
Short Float	11.51%
Short Ratio	4.97
Short Interest	14.52M
52W High	49.20 -6.54%
52W Low	7.96 477.63%
Volatility	7.38% 7.43%
ATR (14)	3.10
RSI (14)	67.94
Beta	2.23
Rel Volume	0.49
Avg Volume	2.92M
Volume	1,416,724

Perf Week	3.37%
Perf Month	90.71%
Perf Quarter	106.65%
Perf Half Y	232.23%
Perf YTD	243.39%
Perf Year	451.98%
Perf 3Y	1055.28%
Perf 5Y	-7.67%
Perf 10Y	-
Recom	1.06
Target Price	57.80
Prev Close	43.65
Price	45.98
Change	5.34%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-23-26	Reiterated	Needham	Buy	$38 → $50
Apr-17-26	Initiated	Stifel	Buy	$30
Apr-10-26	Initiated	Piper Sandler	Overweight	$49
Feb-24-26	Initiated	Wolfe Research	Outperform	$25
Jan-30-26	Initiated	Jefferies	Buy	$30
Oct-13-25	Initiated	Needham	Buy	$28
Aug-04-25	Resumed	Oppenheimer	Outperform	$25
Jan-28-25	Initiated	Evercore ISI	Outperform	$23
Dec-20-24	Initiated	Chardan Capital Markets	Buy	$20
Oct-14-24	Resumed	Leerink Partners	Outperform	$20
Jul-24-24	Initiated	ROTH MKM	Buy	$36
May-29-24	Initiated	Robert W. Baird	Outperform	$27
Apr-15-24	Initiated	Leerink Partners	Outperform	$20
Dec-05-23	Initiated	Canaccord Genuity	Buy	$9
Dec-09-22	Resumed	ROTH Capital	Buy	$25
Nov-16-22	Initiated	RBC Capital Mkts	Outperform	$5
Aug-26-22	Initiated	Oppenheimer	Outperform	$3.50
Aug-10-22	Initiated	Cantor Fitzgerald	Overweight	$3
May-04-22	Initiated	ROTH Capital	Buy	$7
Jun-28-21	Initiated	Maxim Group	Buy	$6

Show Previous Ratings

Jul-14-26 03:00PM	The Race to Commercialize the Worlds Most Powerful Psychedelic (WSJ) +5.34%
07:00AM	New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD) (Business Wire)
Jul-09-26 06:38PM	Leaderboard Quarterly Scorecard Webinar Q&A Summary For Thursday, July 9, 2026 (Investor's Business Daily) +6.91%
Jun-26-26 09:30AM	A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year (PR Newswire)
07:53AM	FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services (BioPharma Dive)
04:15PM	Loading…
Jun-25-26 04:15PM	Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters Option to Purchase Additional Shares (Business Wire) +6.31%
Jun-24-26 06:56AM	To Wall Street, psychedelics biotechs are more teammates than rivals (BioPharma Dive) +16.45%
Jun-23-26 09:57PM	Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering (Business Wire)
Jun-22-26 07:52PM	DFTX Stock Clocks Best Day In Over Two Years On 'Best-Case' Clinical Results For Oral Lysergide In Depression (Stocktwits) +49.80%
06:40PM	?? Under the Radar: Definium Shares Propelled by Strong Psychedelic Results (The Wall Street Journal)
04:08PM	This Biotech's LSD-Based Drug Just Treated Depression. Now The Stock Is Sky-High. (Investor's Business Daily)
04:01PM	Definium Therapeutics, Inc. Announces Proposed Public Offering (Business Wire)
01:36PM	Definium Therapeutics shares surge on positive late-stage trial results for LSD-based depression therapy (Proactive)
07:12AM	Sanofi swaps R&D leaders; Mercks Prometheus deal pays dividends (BioPharma Dive)
06:35AM	DFTX Stock Rallies Ahead Of High-Stakes Phase 3 Depression Drug Trial Results What Investors Need To Know (Stocktwits)
07:00AM	Loading…
May-21-26 07:00AM	Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference (Business Wire) +8.53%
May-18-26 10:03AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
May-12-26 07:00AM	Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder (Business Wire)
May-11-26 04:01PM	Definium Therapeutics Announces New Employee Inducement Grants (Business Wire)
May-07-26 04:01PM	Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights (Business Wire)
Apr-30-26 04:01PM	Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026 (Business Wire) +6.78%
Apr-24-26 11:58AM	Psychedelic Pharma Stocks Are Riding High. Past Cannabis Returns Are a Reality Check. (Barrons.com)
Apr-22-26 04:15PM	Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day (Business Wire)
Apr-20-26 04:01PM	Definium Therapeutics Announces New Employee Inducement Grants (Business Wire)
10:20AM	Market Minute 4-20-26- Oil Pops, Stocks Slide on Fading Peace Hopes (MoneyShow)
08:26AM	Psychedelic stocks rally with Trump's support (MarketWatch)
05:53AM	Psychedelic stocks soar after Trump signs executive order to fast-track treatments (Investing.com)
Apr-18-26 07:38PM	Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments (Business Wire)
Apr-17-26 04:00AM	Can an LSD candidate do for anxiety what Spravato did for depression? (Pharma Voice)
Apr-09-26 07:00AM	Definium Therapeutics to Participate at Upcoming Investor Conferences and Events (Business Wire)
09:08AM	Loading…
Apr-06-26 09:08AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Mar-26-26 07:00AM	Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026 (Business Wire)
Mar-09-26 04:01PM	Definium Therapeutics Announces New Employee Inducement Grants (Business Wire)
10:50AM	CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions (PR Newswire)
Mar-06-26 10:15AM	Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results (TipRanks)
Feb-27-26 11:44AM	Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments (PR Newswire)
12:06AM	Definium Therapeutics Inc (DFTX) Q4 2025 Earnings Call Highlights: Strong Financial Position ... (GuruFocus.com)
Feb-26-26 11:13PM	Definium Therapeutics Q4 Earnings Call Highlights (MarketBeat)
04:01PM	Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates (Business Wire)
Feb-24-26 07:01AM	Definium Therapeutics to Participate at Upcoming Investor Conferences (Business Wire)
Feb-19-26 04:01PM	Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026 (Business Wire)
Feb-18-26 09:32PM	Jefferies Assigns 65-75% Probability of Best-in-Class Efficacy for Definium Therapeutics, Inc.'s (DFTX) DT120 in Phase III (Insider Monkey)
04:25AM	Psychedelics stocks rise as Compass psilocybin drug heads to FDA (BioPharma Dive)
Feb-02-26 04:00PM	Definium Therapeutics Announces New Employee Inducement Grants (Business Wire) +8.00%
Jan-30-26 09:54AM	Spotify upgraded, Pinterest downgraded: Wall Street's top analyst calls (The Fly)
Jan-29-26 07:00AM	Definium Therapeutics Appoints Roger Adsett to Board of Directors (Business Wire)
Jan-26-26 04:01PM	Definium Therapeutics Announces New Employee Inducement Grants (Business Wire) -5.11% +5.88%
09:55AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Jan-20-26 07:00AM	Definium Therapeutics Introduces Rerouting Minds, an Educational Campaign Exploring the Potential of Pharmaceutical Lysergide (LSD) in Mental Health Care (Business Wire) +11.50%
Dec-29-25 09:50AM	MNMD Stock Up More Than 100% in 6 Months: What's in Store for 2026? (Zacks)
Dec-27-25 07:40AM	What's Driving JonesTrading's Bullish View on Mind Medicine (MindMed) Inc. (MNMD) (Insider Monkey)
Dec-23-25 09:33AM	Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls (The Fly) +5.41%
Dec-22-25 01:12PM	MarketBeat's Top 5 Rated Small-Cap Stocks (MarketBeat)
Dec-18-25 07:01AM	MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-16-25 09:23AM	5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026 (Zacks)
Dec-15-25 04:01PM	MindMed Announces New Employee Inducement Grant (Business Wire)
Dec-01-25 04:01PM	MindMed Announces New Employee Inducement Grants (Business Wire)
Nov-07-25 12:03AM	Mind Medicine Inc (MNMD) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ... (GuruFocus.com)
Nov-06-25 04:01PM	MindMed Reports Q3 2025 Financial Results and Business Updates (Business Wire)
Nov-05-25 07:01AM	MindMed to Participate in Upcoming Investor Conferences (Business Wire)
Nov-03-25 04:01PM	MindMed Announces New Employee Inducement Grant (Business Wire) -13.45%
07:01AM	Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares (Business Wire)
Oct-30-25 04:01PM	MindMed to Report Q3 2025 Financial Results on November 6, 2025 (Business Wire) +6.05%
Oct-29-25 10:14PM	Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering (Business Wire)
04:01PM	Mind Medicine (MindMed) Inc. Announces Proposed Public Offering (Business Wire)
Oct-14-25 04:01PM	MindMed Announces New Employee Inducement Grant (Business Wire)
Sep-22-25 04:01PM	MindMed Announces New Employee Inducement Grants (Business Wire) +5.53%
Sep-21-25 09:06PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Sep-19-25 07:00AM	New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD) (Business Wire)
Sep-08-25 04:01PM	MindMed Announces New Employee Inducement Grants (Business Wire)
Sep-04-25 11:05AM	Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD) (Business Wire)
Sep-02-25 03:47AM	Mind Medicine (MindMed) Inc. (MNMD)'s MM120 Earns FDA Breakthrough Status in Anxiety Treatment (Insider Monkey)
Aug-28-25 07:00AM	MindMed to Participate in September Investor Conferences (Business Wire)
Aug-12-25 03:43AM	If You'd Invested $1,000 in Mind Medicine (MNMD) Stock 5 Years Ago, Here's How Much You'd Have Today (Motley Fool)
Aug-11-25 04:01PM	MindMed Announces New Employee Inducement Grants (Business Wire)
Aug-07-25 05:25AM	1 Reason to Buy MindMed (MNMD) (Motley Fool)
Aug-01-25 03:36AM	Mind Medicine Inc (MNMD) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial ... (GuruFocus.com) -7.15%
Jul-31-25 04:01PM	MindMed Reports Q2 2025 Financial Results and Business Updates (Business Wire)
Jul-25-25 09:40AM	Is Anixa Biosciences (ANIX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jul-24-25 07:00AM	MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025 (Business Wire)
Jul-22-25 12:00PM	All You Need to Know About Mind Medicine MindMed (MNMD) Rating Upgrade to Buy (Zacks)
Jul-14-25 04:01PM	MindMed Announces New Employee Inducement Grants (Business Wire)
Jun-27-25 11:50AM	Psychedelic: Compass Pathways achieves primary endpoint in COMP360 trial (TipRanks)
Jun-19-25 10:10AM	Trump Trade: President said to weigh possible U.S. strike against Iran (TipRanks)
09:26AM	Psychedelic advocates hopeful Trump administration will support space, STAT says (TipRanks)
12:01AM	This Illegal Psychedelic Is Hailed as a Revolutionary Breakthrough (WSJ)
Jun-09-25 04:01PM	MindMed Announces New Employee Inducement Grants (Business Wire)
Jun-04-25 07:02AM	Why Mind Medicine Gave Investors a Powerful Buzz in May (Motley Fool)
Jun-02-25 09:55AM	Wall Street Analysts Believe Mind Medicine MindMed (MNMD) Could Rally 237.47%: Here's is How to Trade (Zacks)
May-28-25 07:00AM	MindMed to Participate in June Investor Conferences (Business Wire)
May-27-25 07:00AM	MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer (Business Wire)
May-21-25 11:18AM	Mind Medicine (MindMed) Inc. (MNMD): Analysts See 285% Upside Potential (Insider Monkey) -8.68%
May-20-25 05:33PM	Why Mind Medicine Stock Vaulted More Than 8% Higher Today (Motley Fool) +8.42%
May-19-25 04:01PM	MindMed Announces New Employee Inducement Grants (Business Wire) +6.21%
May-16-25 04:17PM	Was Jim Cramer Right About Mind Medicine (MNMD) Stock? (Insider Monkey)
May-13-25 09:55AM	Does Mind Medicine MindMed (MNMD) Have the Potential to Rally 279.84% as Wall Street Analysts Expect? (Zacks)
07:00AM	MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference (Business Wire)
May-09-25 11:11AM	Psychedelic: Compass, GH Research, MindMed report quarterly earnings (TipRanks)
May-08-25 07:00AM	MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates (Business Wire)
May-07-25 12:33PM	Mind Medicine Q1 2025 Earnings Preview (Seeking Alpha)

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

CEO & DirectorMr. Robert Barrow

M.B.A.Ms. Brandi L. Roberts CPA

M.D.Dr. Daniel Rollings Karlin M.A.

Co-Founder & Clinical AdvisorDr. Scott M. Freeman M.D.

Co-FounderMr. Leonard Latchman

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sullivan Mark	Chief Legal Officer	Jun 25 '26	Sale	45.03	13,008	585,750	320,571	Jun 26 04:30 PM
Roberts Brandi	Chief Financial Officer	Jun 25 '26	Sale	45.03	3,013	135,675	209,487	Jun 26 04:30 PM
Barrow Robert	Chief Executive Officer	Jun 25 '26	Sale	45.03	29,208	1,315,236	1,098,246	Jun 26 04:30 PM
Karlin Daniel	Chief Medical Officer	Jun 25 '26	Sale	45.03	10,035	451,876	503,282	Jun 26 04:30 PM
Wiley Matthew T.	Chief Commercial Officer	Jun 25 '26	Sale	45.03	2,867	129,101	174,633	Jun 26 04:30 PM
MARK SULLIVAN	Officer	Jun 25 '26	Proposed Sale	42.13	13,008	548,027		Jun 25 04:10 PM
MATTHEW THOMAS WILEY	Officer	Jun 25 '26	Proposed Sale	42.13	2,867	120,787		Jun 25 04:09 PM
BRANDI ROBERTS	Officer	Jun 25 '26	Proposed Sale	42.13	3,013	126,938		Jun 25 04:08 PM
DANIEL ROLLINGS KARLIN	Officer	Jun 25 '26	Proposed Sale	42.13	10,035	422,775		Jun 25 04:07 PM
ROBERT B BARROW	Officer	Jun 25 '26	Proposed Sale	42.13	29,208	1,230,533		Jun 25 04:06 PM
Karlin Daniel	Chief Medical Officer	Mar 25 '26	Sale	18.47	8,018	148,092	413,317	Mar 26 06:43 PM
Sullivan Mark	Chief Legal Officer	Mar 25 '26	Sale	18.47	10,702	197,666	271,079	Mar 26 06:42 PM
Barrow Robert	Chief Executive Officer	Mar 25 '26	Sale	18.47	24,431	451,241	752,454	Mar 26 06:42 PM
ROBERT B BARROW	Officer	Mar 25 '26	Proposed Sale	18.47	24,431	451,241		Mar 25 05:41 PM
DANIEL ROLLINGS KARLIN	Officer	Mar 25 '26	Proposed Sale	18.47	8,018	148,092		Mar 25 05:40 PM
MARK SULLIVAN	Officer	Mar 25 '26	Proposed Sale	18.47	10,702	197,666		Mar 25 05:39 PM
Karlin Daniel	Chief Medical Officer	Dec 26 '25	Sale	13.15	5,600	73,623	425,025	Dec 29 05:00 PM
Barrow Robert	Chief Executive Officer	Dec 26 '25	Sale	13.15	25,791	339,072	778,477	Dec 29 05:00 PM
Sullivan Mark	Chief Legal Officer	Dec 26 '25	Sale	13.15	11,276	148,244	282,576	Dec 29 05:00 PM
Karlin, Dan	Officer	Dec 26 '25	Proposed Sale	13.15	5,600	73,623		Dec 29 04:15 PM
Sullivan, Mark	Officer	Dec 26 '25	Proposed Sale	13.15	11,276	148,244		Dec 29 04:15 PM
Barrow, Robert	Officer, Director	Dec 26 '25	Proposed Sale	13.15	25,791	339,072		Dec 29 04:15 PM
Sullivan Mark	Chief Legal Officer	Sep 25 '25	Sale	9.77	11,278	110,186	293,852	Sep 26 05:35 PM
Barrow Robert	Chief Executive Officer	Sep 25 '25	Sale	9.77	25,797	252,037	804,268	Sep 26 05:35 PM
Karlin Daniel	Chief Medical Officer	Sep 25 '25	Sale	9.77	7,704	75,268	430,625	Sep 26 05:34 PM
MARK SULLIVAN	Officer	Sep 25 '25	Proposed Sale	9.77	11,278	110,217		Sep 25 04:43 PM
DANIEL ROLLINGS KARLIN	Officer	Sep 25 '25	Proposed Sale	9.77	7,704	75,289		Sep 25 04:40 PM
ROBERT B BARROW	Officer	Sep 25 '25	Proposed Sale	9.77	25,797	252,106		Sep 25 04:38 PM

Open in Screener

BTAI

BioXcel Therapeutics Inc

1.03

Jul 14 • 03:59PM ET +0.15 (16.75%)

1.03

Aftermarket • 07:59PM ET 0.00 (0.00%)

Healthcare Drug Manufacturers - Specialty & Generic USA Nano NASD

BTAI BioXcel Therapeutics Inc daily Stock Chart

Peers: INCR TLPH ZYBT CRDL DERM ANIK ASRT LFCR TKNO OPTH

| Held by: VXF IWC BTEC

Index	-
Market Cap	31.80M
Enterprise Value	114.91M
Income	-75.33M
Sales	0.68M
Book/sh	-3.90
Cash/sh	0.56
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	29
IPO	Mar 08, 2018

P/E	-
Forward P/E	-
PEG	-
P/S	46.76
P/B	-
P/C	1.85
P/FCF	-
EV/EBITDA	-
EV/Sales	168.99
Quick Ratio	0.61
Current Ratio	0.62
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-6.19
EPS next Y	-1.53
EPS next Q	-0.42
EPS this Y	70.90%
EPS next Y	8.05%
EPS next 5Y	48.34%
EPS past 3/5Y	60.75% 37.62%
Sales past 3/5Y	19.63% -
EPS Y/Y TTM	54.23%
Sales Y/Y TTM	-63.28%
EPS Q/Q	64.12%
Sales Q/Q	22.62%
Earnings	May 15 BMO
EPS/Sales Surpr.	-1.41% -46.00%

Insider Own	4.63%
Insider Trans	-2.70%
Inst Own	18.72%
Inst Trans	-0.69%
ROA	-207.56%
ROE	-
ROIC	-
Gross Margin	-5.15%
Oper. Margin	-7344.26%
Profit Margin	-11078.53%
SMA20	-11.40%
SMA50	-12.07%
SMA200	-36.63%
Trades

Shs Outstand	30.88M
Shs Float	29.45M
Short Float	12.44%
Short Ratio	3.95
Short Interest	3.66M
52W High	8.08 -87.25%
52W Low	0.74 39.85%
Volatility	21.79% 11.08%
ATR (14)	0.12
RSI (14)	45.15
Beta	0.30
Rel Volume	5.20
Avg Volume	928.34K
Volume	4,830,273

Perf Week	-0.96%
Perf Month	-7.21%
Perf Quarter	0.98%
Perf Half Y	-48.76%
Perf YTD	-35.63%
Perf Year	-49.01%
Perf 3Y	-99.38%
Perf 5Y	-99.76%
Perf 10Y	-
Recom	1.60
Target Price	14.60
Prev Close	0.88
Price	1.03
Change	16.75%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-17-26	Initiated	Rodman & Renshaw	Buy	$17
Feb-21-24	Downgrade	UBS	Buy → Neutral	$9 → $4
Aug-15-23	Downgrade	Mizuho	Buy → Neutral	$40 → $4
Jul-17-23	Downgrade	Guggenheim	Buy → Neutral
Mar-10-23	Downgrade	Jefferies	Buy → Hold	$20 → $22
Dec-01-22	Upgrade	Goldman	Sell → Neutral	$16
Jul-07-22	Initiated	Mizuho	Buy	$19
Apr-06-22	Reiterated	BofA Securities	Buy	$80
Nov-15-21	Downgrade	Goldman	Neutral → Sell	$55 → $24
Apr-09-21	Initiated	Berenberg	Buy	$75
Feb-01-21	Initiated	UBS	Buy	$99
Oct-30-20	Initiated	Goldman	Buy	$60
Sep-02-20	Initiated	Jefferies	Buy	$82
Aug-17-20	Reiterated	H.C. Wainwright	Buy	$200 → $175
Jul-08-20	Reiterated	H.C. Wainwright	Buy	$95 → $120
Jun-04-20	Initiated	Guggenheim	Buy	$101
Apr-01-20	Initiated	BofA/Merrill	Buy	$45
Feb-26-20	Reiterated	H.C. Wainwright	Buy	$30 → $95
Jan-08-20	Reiterated	H.C. Wainwright	Buy	$25 → $30
Nov-12-19	Initiated	SunTrust	Buy	$24

Show Previous Ratings

May-28-26 07:00AM	BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting (GlobeNewswire)
May-15-26 07:00AM	BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results (GlobeNewswire) -5.79%
Apr-17-26 07:00AM	BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI in the At-Home Setting (GlobeNewswire) +7.48%
Apr-09-26 07:53PM	Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? (PR Newswire)
Apr-08-26 07:00AM	BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions (GlobeNewswire)
07:00AM	Loading…
Apr-01-26 07:00AM	BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI in the At-Home Setting (GlobeNewswire) -8.96%
Mar-27-26 07:00AM	BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI Approval in Outpatient Setting (GlobeNewswire) -8.03%
Mar-11-26 04:20PM	BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering (GlobeNewswire)
Mar-10-26 02:36PM	BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering (GlobeNewswire) -10.40%
Mar-06-26 10:27AM	Why Are BioXcel Therapeutics Shares Down Friday? (Benzinga) -8.07%
Mar-05-26 08:53AM	BioXcel Therapeutics Stock Rallies Opioid Study Success (Benzinga)
07:00AM	BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal (GlobeNewswire)
Feb-19-26 07:00AM	BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer's Dementia (GlobeNewswire)
Feb-12-26 07:00AM	BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI in the At-Home Setting (GlobeNewswire)
Jan-20-26 07:00AM	BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI Label Expansion in the At-Home Setting (GlobeNewswire)
12:00PM	Loading…
Jan-17-26 12:00PM	1 Top Penny Stock to Watch Now (Barchart)
Jan-15-26 12:44PM	Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
Jan-12-26 07:00AM	BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI in the At-Home Setting (GlobeNewswire)
Jan-07-26 07:00AM	BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI (GlobeNewswire) +17.24%
Dec-03-25 07:00AM	Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions (GlobeNewswire)
Nov-12-25 08:25AM	BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -15.35%
07:00AM	BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer's Disease (GlobeNewswire)
Oct-24-25 11:38AM	Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
Oct-14-25 07:00AM	BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes (GlobeNewswire)
Oct-13-25 07:00AM	BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation (GlobeNewswire)
Sep-18-25 07:00AM	BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements (GlobeNewswire)
Sep-10-25 06:30AM	BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire)
Sep-04-25 07:00AM	BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-29-25 07:28AM	BioXCel seeks Igalmi label expansion after Phase III success (Clinical Trials Arena)
Aug-27-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -24.43%
08:00AM	Loading…
08:00AM	UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI (GlobeNewswire)
07:00AM	BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI (GlobeNewswire)
Aug-26-25 04:00PM	BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025 (GlobeNewswire)
Aug-19-25 07:00AM	BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire) -13.23%
Aug-18-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
07:00AM	BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire)
Aug-13-25 12:33PM	3 Supercharged Stocks Flashing Strong Momentum Signals (Benzinga) -17.65%
10:30AM	BC-Most Active Stocks (Associated Press Finance)
07:00AM	BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. "HCW@Home" Series (GlobeNewswire)
Aug-12-25 03:00PM	BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +6.25%
07:55AM	BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates (GlobeNewswire)
Aug-11-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +58.42%
07:00AM	BioXcel Therapeutics to Participate in Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire)
Aug-08-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +18.48%
Aug-07-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
Aug-06-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +11.78%
07:00AM	BioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in Non-clinical Studies (GlobeNewswire)
Aug-04-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +85.40%
Aug-01-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
07:00AM	BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire)
Jul-21-25 07:00AM	BioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMI (GlobeNewswire)
Jul-14-25 11:33AM	FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock Tanks (Zacks)
Jul-11-25 07:27PM	BioXcel Therapeutics, Inc. (BTAI) Retains Buy Rating on Positive Trial Progress (Insider Monkey)
Jul-01-25 07:00AM	BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire) +8.84%
May-30-25 09:09AM	Real-World Deployments Signal AI Healthcare Is Ready for Scale (PR Newswire)
May-27-25 08:01AM	BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire)
07:00AM	BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement (GlobeNewswire)
May-12-25 08:15AM	BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-06-25 09:15AM	Krystal Biotech, Inc. (KRYS) Misses Q1 Earnings and Revenue Estimates (Zacks) -7.60%
May-05-25 05:15PM	Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
Apr-16-25 08:58AM	WHO and WEF Are Pushing AI in Global Healthcare -- What It Means for the Market (PR Newswire)
Mar-27-25 08:15AM	BioXcel Therapeutics, Inc. (BTAI) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +5.96%
07:00AM	BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024 (GlobeNewswire)
Mar-20-25 06:50PM	TELA Bio, Inc. (TELA) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Mar-19-25 05:10PM	ScPharmaceuticals, Inc. (SCPH) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +7.73%
02:13PM	Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight (Zacks)
Mar-11-25 07:00AM	BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire) -16.84%
Mar-09-25 06:05PM	Why BioXcel Therapeutics, Inc. (BTAI) Soared Last Week (Insider Monkey)
Mar-07-25 07:00AM	BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire) +22.99%
Mar-04-25 04:15PM	BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering (GlobeNewswire) -28.00%
10:00AM	BioXcel Therapeutics, Inc. (BTAI) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks)
Mar-03-25 03:33PM	BioXcel Therapeutics Announces $14 Million Registered Direct Offering (GlobeNewswire) +73.61%
07:00AM	BioXcel Therapeutics Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer's Dementia (GlobeNewswire)
Feb-28-25 07:00AM	BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule (GlobeNewswire) +24.86%
Feb-06-25 07:00AM	BioXcel Therapeutics Announces Reverse Stock Split (GlobeNewswire) -37.57%
Feb-05-25 07:00AM	BioXcel Therapeutics Provides Clinical and Business Update (GlobeNewswire)
Dec-23-24 12:00PM	BioXcel Therapeutics (BTAI) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Nov-22-24 08:16AM	BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering (GlobeNewswire) -10.80%
Nov-21-24 04:47PM	BioXcel Therapeutics Announces Proposed Public Offering (GlobeNewswire)
Nov-15-24 02:07AM	BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ... (GuruFocus.com) +9.20%
Nov-14-24 11:13PM	Q3 2024 BioXcel Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -15.93%
08:20AM	BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:00AM	BioXcel Therapeutics Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-13-24 07:31AM	What To Expect From BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings (GuruFocus.com) -6.92%
Nov-12-24 07:00AM	BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer's Dementia (GlobeNewswire) -7.61%
Nov-08-24 07:00AM	BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024 (GlobeNewswire)
Nov-05-24 10:00AM	Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know (Zacks)
Oct-29-24 07:00AM	BioXcel Therapeutics to Present at ThinkEquity Conference (GlobeNewswire) +6.57%
Oct-15-24 07:00AM	BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder (GlobeNewswire) +6.06%
Sep-19-24 07:00AM	BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation (GlobeNewswire)
Sep-12-24 01:22AM	FMR LLC's Strategic Reduction in BioXcel Therapeutics Inc Shares (GuruFocus.com)
Sep-05-24 07:00AM	BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire)
Aug-30-24 09:55AM	BioXcel Therapeutics (BTAI) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Aug-07-24 07:00AM	BioXcel Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference (GlobeNewswire) -5.06%
01:31AM	Q2 2024 BioXcel Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-06-24 08:10AM	BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	BioXcel Therapeutics Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-30-24 07:00AM	BioXcel Therapeutics to Report Second Quarter 2024 Financial Results on August 6, 2024 (GlobeNewswire) -6.84%
Jul-16-24 07:00AM	BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI (dexmedetomidine) Sublingual Film (GlobeNewswire) +9.84%

BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. It also focuses on utilizing technology and research to develop therapeutics solutions. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.

FounderDr. Vimal D. Mehta Ph.D.

Senior VP & CFOMr. Richard I. Steinhart MBA

Senior VPMr. Javier Rodriguez J.D.

Executive VP & Chief Scientific OfficerDr. Frank D. Yocca Ph.D.

Acting Chief Commercial OfficerMr. Mark H. Pavao

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Yocca Frank	Chief Scientific Officer	May 20 '26	Sale	1.08	6,845	7,427	26,175	May 22 07:02 PM
Rodriguez Javier	See Remarks	May 20 '26	Sale	1.08	6,560	7,111	26,803	May 22 07:02 PM
Steinhart Richard I	Chief Financial Officer	May 20 '26	Sale	1.08	6,845	7,427	26,300	May 22 07:01 PM
Mehta Vimal	CEO and President	May 20 '26	Sale	1.09	19,419	21,108	69,598	May 22 07:00 PM
Mehta Vimal	Officer	May 20 '26	Proposed Sale	1.09	19,419	21,114		May 20 04:29 PM
Rodriguez Javier	Officer	May 20 '26	Proposed Sale	1.08	6,560	7,109		May 20 04:27 PM
Yocca Frank	Officer	May 20 '26	Proposed Sale	1.09	6,845	7,430		May 20 04:26 PM
Steinhart Richard I	Officer	May 20 '26	Proposed Sale	1.08	6,845	7,426		May 20 04:25 PM

DFTX

Definium Therapeutics Inc

BTAI

BioXcel Therapeutics Inc

Upgrade your Finviz experience